The bactericidal activity against Streptococcus pneumoniae of XRP2868, a new oral streptogramin composed of two semi-synthetic synergistic components in a 30/70 (w/w) association (RPR202868, pristinamycin I derivative and RPR132552, pristinamycin II derivative), was assessed in lungs of mice with pneumonia.